biostudies-literatureKozminsky MU.S. Department of DefenseA. Alfred Taubman Medical Research InstituteNCI NIH HHSNational Institutes of HealthProstate Cancer FoundationNIH HHSNational Science Foundation1801254https://www.ebi.ac.uk/biostudies/studies/S-EPMC6343066biostudies-literatureUnknown6(2)Rates of progression and treatment response in advanced prostate cancer are highly variable, necessitating non-invasive methods to assess the molecular characteristics of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA expression. A microfluidic graphene oxide-based device (GO Chip) is used to isolate CTCs and CTC clusters from the whole blood of 41 men with metastatic castration-resistant prostate cancer. Additionally, the expression of 96 genes of interest is determined by RT-qPCR. Multivariate analyses are conducted to determine the genes most closely associated with overall survival, PSA progression, and radioclinical progression. A preliminaAdvanced science (Weinheim, Baden-Wurttemberg, Germany)Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer.PMC63430661DP2OD006672‐01DGE 1256260DP2 OD006672W81XWH‐14‐1‐0287R33 CA202867R01 CA208335Azizi EFouladdel SSmith DCAlva AMorgan TNagrath SChung JSWang YKozminsky MfalseDetection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer.Rates of progression and treatment response in advanced prostate cancer are highly variable, necessitating non-invasive methods to assess the molecular characteristics of these tumors in real time. The unique potential of circulating tumor cells (CTCs) to serve as a clinically useful liquid biomarker is due to their ability to inform via both enumeration and RNA expression. A microfluidic graphene oxide-based device (GO Chip) is used to isolate CTCs and CTC clusters from the whole blood of 41 men with metastatic castration-resistant prostate cancer. Additionally, the expression of 96 genes of interest is determined by RT-qPCR. Multivariate analyses are conducted to determine the genes most closely associated with overall survival, PSA progression, and radioclinical progression. A prelimina2019-01-01T00:00:00Z2019 Jan2025-04-04T19:07:34.248Z2019-03-26T22:43:46ZS-EPMC63430663069318210.1002/advs.201801254